TABLE 3.
Comparison of pre and post added empagliflozin therapy differences in parameters between Group 1 and Group 2
| Compared parameters | Change from baseline treatment | p | |
|---|---|---|---|
| Group 1 | Group 2 | ||
| Δ HbA1c, % | -1.54±2.14 | -1.18±1.5 | 0.935 |
| Δ FPG, mg/dl | -39.0±94.1 | -36.7±81.1 | 0.739 |
| Δ Creatinine, mg/dl | 0.01±0.10 | 0.03±011 | 0.067 |
| Δ eGFR, mL/min per 1.73 m2 | -2.4±14.5 | -5.1±17.6 | 0.068 |
| Δ Total cholesterol, mg/dL | -23.1±38.5 | -9.6±19.9 | 0.313 |
| Δ LDL-cholesterol, mg/dL | -7.6±36.0 | -12.0±21.2 | 0.299 |
| Δ HDL-cholesterol, mg/dL | 0.5±7.6 | 4.2±7.9 | 0.267 |
| Δ Triglyceride, mg/dL | -58.2±181.2 | -2.7±47.4 | 0.224 |
| Δ Weight, kg | -2.6±1.2 | -3.8±2,0 | 0.021 |
| Δ SBP, mmHg | -6.8±5.1 | -9.6±7.5 | 0.032 |
| Δ DBP, mmHg | -4.6±4.0 | -6.7±4.6 | 0.005 |
FPG: Fasting plasma glucose; HbA1c: Glycosylated haemoglobin; eGFR: Estimated glomerular filtration rate [using the Modification of Diet in Renal Disease (MDRD) equation]; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.